Actavis PLC (ACT.N)

ACT.N on New York Stock Exchange

216.89USD
1:35am IST
Price Change (% chg)

$2.63 (+1.23%)
Prev Close
$214.26
Open
$213.87
Day's High
$217.99
Day's Low
$213.60
Volume
895,329
Avg. Vol
362,570
52-wk High
$230.57
52-wk Low
$130.25

ACT.N

Chart for ACT.N

About

Actavis PLC, is a global, integrated specialty pharmaceutical company. The Company focused on developing, manufacturing and distributing generic, brand and biosimilar products. The Company produces and markets generic, branded generic, branded and over-the-counter (OTC) pharmaceutical products covering all therapeutic classes.... (more)

Overall

Beta: 0.35
Market Cap (Mil.): $56,795.08
Shares Outstanding (Mil.): 265.08
Dividend: --
Yield (%): --

Financials

  ACT.N Industry Sector
P/E (TTM): -- 35.76 36.20
EPS (TTM): -4.08 -- --
ROI: -3.60 18.79 18.07
ROE: -8.33 19.47 18.86
Search Stocks

UPDATE 3-AstraZeneca buys Almirall lung drugs for up to $2.1 billion

* Initial $875 mln payout, up to $1.22 bln more if goals hit

30 Jul 2014

U.S. allows Actavis Plc's purchase of Forest Labs with conditions

WASHINGTON - Generic drugmaker Actavis Plc has won U.S. approval to buy specialty pharmaceuticals company Forest Laboratories on condition it sell or relinquish the rights to four generic medicines, the Federal Trade Commission said on Monday.

01 Jul 2014

UPDATE 1-U.S. allows Actavis Plc's purchase of Forest Labs with conditions

(Adds details of drugs to be divested, share price, other pharma deals)

01 Jul 2014

U.S. allows Actavis Plc's purchase of Forest Labs with conditions

WASHINGTON, June 30 - Pharmaceutical company Actavis Plc has won U.S. approval to buy Forest Laboratories on condition that it sell or relinquish the rights to four generic medicines, the Federal Trade Commission said on Monday.

01 Jul 2014

Acorda's multiple sclerosis drug faces generic threat

June 26 - Acorda Therapeutics Inc said Actavis Plc plans to market a generic version of Acorda's multiple sclerosis treatment, Ampyra.

26 Jun 2014

Forest antidepressant Viibryd succeeds in anxiety disorder trials

June 23 - Forest Laboratories Inc, which is being acquired by generic drugmaker Actavis Plc, said on Monday that its antidepressant Viibryd performed significantly better than a placebo for treating generalized anxiety disorder, according to data from three late-stage studies.

24 Jun 2014

BRIEF-U.S. appeals court rules for Novartis, Actavis, Apotex and against Allergan, Duke over patents related to eyelash growth

June 10 - Novartis AG : * Actavis PLC apotex inc win reversal of lower court ruling regarding

10 Jun 2014

Fitch Rates New Actavis Bonds 'BBB-'; Outlook Stable

(The following statement was released by the rating agency) CHICAGO, June 10 (Fitch) Fitch Ratings has assigned a 'BBB-' rating to new senior unsecured bonds to be issued by an indirect subsidiary of Actavis plc (NYSE: ACT). Fitch has also assigned a 'BBB-' Issuer Default Rating (IDR) to Actavis Funding SCS, the issuer of the bonds, and Warner Chilcott Limited. ACT's IDR is 'BBB-', with a Stable Outlook. A full list of ratings for ACT follows at the end of this release. The new unsecured no

10 Jun 2014

Forest Labs wins U.S. antitrust approval to buy Furiex

WASHINGTON - Forest Laboratories Inc, which itself is in the process of being acquired, has won U.S. antitrust approval to buy Furiex Pharmaceuticals Inc, the Federal Trade Commission said on Friday.

30 May 2014

Eli Lilly loses UK Alimta patent case to Actavis

LONDON - Eli Lilly and Co LLY.N has lost a patent case in the English High Court over its blockbuster Alimta lung cancer drug to generic drugmaker Actavis Plc ACT.N, dealing a blow to the U.S. drugmaker's future sales hopes.

15 May 2014

Earnings vs. Estimates

Search Stocks